HUE051625T2 - B-sejtes rosszindulatú daganatok kezelése JAK és PI3K inhibitorok kombinációjával - Google Patents
B-sejtes rosszindulatú daganatok kezelése JAK és PI3K inhibitorok kombinációjávalInfo
- Publication number
- HUE051625T2 HUE051625T2 HUE15717381A HUE15717381A HUE051625T2 HU E051625 T2 HUE051625 T2 HU E051625T2 HU E15717381 A HUE15717381 A HU E15717381A HU E15717381 A HUE15717381 A HU E15717381A HU E051625 T2 HUE051625 T2 HU E051625T2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- pi3k inhibitor
- cell malignancies
- jak
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461976815P | 2014-04-08 | 2014-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE051625T2 true HUE051625T2 (hu) | 2021-03-29 |
Family
ID=52988487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15717381A HUE051625T2 (hu) | 2014-04-08 | 2015-04-07 | B-sejtes rosszindulatú daganatok kezelése JAK és PI3K inhibitorok kombinációjával |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US10064866B2 (hu) |
| EP (2) | EP3795152A1 (hu) |
| JP (4) | JP6537527B2 (hu) |
| KR (3) | KR20230044320A (hu) |
| CN (2) | CN111494386A (hu) |
| AU (3) | AU2015244044B2 (hu) |
| CA (2) | CA2945151C (hu) |
| CL (1) | CL2016002566A1 (hu) |
| CY (1) | CY1123603T1 (hu) |
| DK (1) | DK3129021T3 (hu) |
| EA (2) | EA202191009A1 (hu) |
| ES (1) | ES2829914T3 (hu) |
| HR (1) | HRP20201887T1 (hu) |
| HU (1) | HUE051625T2 (hu) |
| IL (4) | IL295225A (hu) |
| LT (1) | LT3129021T (hu) |
| MA (2) | MA54622A (hu) |
| MX (2) | MX2020004398A (hu) |
| MY (1) | MY185686A (hu) |
| NZ (2) | NZ763326A (hu) |
| PH (1) | PH12016501987A1 (hu) |
| PL (1) | PL3129021T3 (hu) |
| PT (1) | PT3129021T (hu) |
| RS (1) | RS61058B1 (hu) |
| SG (3) | SG10201912229XA (hu) |
| SI (1) | SI3129021T1 (hu) |
| UA (1) | UA119767C2 (hu) |
| WO (1) | WO2015157257A1 (hu) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
| EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈 |
| KR102354472B1 (ko) | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체 |
| EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| JP5876146B2 (ja) | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
| WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| SG10201703533VA (en) * | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| KR102403306B1 (ko) | 2013-01-15 | 2022-06-02 | 인사이트 홀딩스 코포레이션 | Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물 |
| PE20151902A1 (es) | 2013-03-06 | 2015-12-26 | Incyte Corp | Proceso e intermedios para hacer un inhibidor de jak |
| EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| UA119767C2 (uk) | 2014-04-08 | 2019-08-12 | Інсайт Корпорейшн | Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k |
| TW201625643A (zh) | 2014-04-30 | 2016-07-16 | 英塞特公司 | 製備ｊａｋ１抑制劑之方法及其新形式 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
| PL3371190T3 (pl) | 2015-11-06 | 2022-11-07 | Incyte Corporation | Związki heterocykliczne jako inhibitory pi3k-gamma |
| CN108137603B (zh) | 2015-12-11 | 2019-10-18 | 四川科伦博泰生物医药股份有限公司 | 氮杂环丁烷衍生物、其制备方法及用途 |
| ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
| WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| WO2019079469A1 (en) | 2017-10-18 | 2019-04-25 | Incyte Corporation | CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| DK3746429T3 (da) | 2018-01-30 | 2022-05-02 | Incyte Corp | Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on) |
| IL277538B1 (en) | 2018-03-30 | 2024-05-01 | Incyte Corp | Use of JAK inhibitors to treat hidradenitis suppurativa |
| AU2019252793A1 (en) | 2018-04-13 | 2020-10-15 | Sumitomo Pharma Oncology, Inc. | PIM kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
| CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | 南京大学 | 芳基氮杂环丁烷类化合物的制备方法 |
| PT3847175T (pt) | 2018-09-05 | 2024-04-16 | Incyte Corp | Formas cristalinas de um inibidor da fosfoinositídeo 3-quinase (pi3k) |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AR127966A1 (es) | 2021-12-16 | 2024-03-13 | Incyte Corp | Formulaciones tópicas de inhibidores de pi3k-delta |
| WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
| KR102582097B1 (ko) | 2022-12-28 | 2023-09-25 | (주)메디언스 | 야누스키나아제 표적 억제제 및 이의 용도 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| PT1294358E (pt) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | Processo de moagem por via humida |
| CA2466243A1 (en) | 2001-09-19 | 2003-03-27 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
| KR20090087139A (ko) | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| KR20070085433A (ko) | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물 |
| ES2612196T3 (es) | 2005-12-13 | 2017-05-12 | Incyte Holdings Corporation | Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus |
| JP5523829B2 (ja) * | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| BRPI0919488A2 (pt) * | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| CA2702567A1 (en) | 2009-04-28 | 2010-10-28 | Katch Kan Holdings Ltd. | Apparatus and method for stripping solids and fluids from a string used in drilling or servicing wells |
| US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TWI484962B (zh) | 2009-05-22 | 2015-05-21 | Incyte Corp | 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈 |
| AU2010273816B2 (en) * | 2009-06-29 | 2015-07-09 | Incyte Holdings Corporation | Pyrimidinones as PI3K inhibitors |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| CA2766853A1 (en) * | 2009-07-02 | 2011-01-06 | Novartis Ag | 2-carboxamide cycloamino ureas useful as pi3k inhibitors |
| AR077974A1 (es) | 2009-08-28 | 2011-10-05 | Takeda Pharmaceutical | Compuestos de hexahidrooxazinopterina para uso como inhibidores de mtor |
| US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| US20110207754A1 (en) | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| KR102354472B1 (ko) * | 2010-03-10 | 2022-01-21 | 인사이트 홀딩스 코포레이션 | Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체 |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| WO2012068450A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| JP5876146B2 (ja) * | 2011-06-20 | 2016-03-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体 |
| US9358229B2 (en) * | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| AR087760A1 (es) * | 2011-09-02 | 2014-04-16 | Incyte Corp | Heterociclilaminas como inhibidores de pi3k |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| BR112014011645A2 (pt) | 2011-11-15 | 2017-05-02 | Novartis Ag | combinação de um inibidor da fosfoinositida 3-quinase e um modulador da quinase janus 2-transdutor de sinal e ativador da via de transcrição 5 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
| TWI736135B (zh) | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| PE20151902A1 (es) | 2013-03-06 | 2015-12-26 | Incyte Corp | Proceso e intermedios para hacer un inhibidor de jak |
| SI3527263T1 (sl) | 2013-05-17 | 2021-05-31 | Incyte Corporation | Derivati bipirazola kot zaviralci JAK |
| EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| SG11201601119XA (en) | 2013-08-20 | 2016-03-30 | Incyte Corp | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| PL3110409T3 (pl) | 2014-02-28 | 2018-12-31 | Incyte Corporation | Inhibitory jak1 do leczenia zespołów mielodysplastycznych |
| UA119767C2 (uk) | 2014-04-08 | 2019-08-12 | Інсайт Корпорейшн | Лікування b-клітинних злоякісних новоутворень із застосуванням комбінації інгібіторів jak та pi3k |
| TW201625643A (zh) | 2014-04-30 | 2016-07-16 | 英塞特公司 | 製備ｊａｋ１抑制劑之方法及其新形式 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| PT3262046T (pt) | 2015-02-27 | 2020-12-24 | Incyte Corp | Sais de inibidor de pi3k e processos para a sua preparação |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| US20160362424A1 (en) | 2015-05-11 | 2016-12-15 | Incyte Corporation | Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one |
-
2015
- 2015-04-07 UA UAA201611143A patent/UA119767C2/uk unknown
- 2015-04-07 RS RS20201374A patent/RS61058B1/sr unknown
- 2015-04-07 SI SI201531432T patent/SI3129021T1/sl unknown
- 2015-04-07 PL PL15717381T patent/PL3129021T3/pl unknown
- 2015-04-07 EA EA202191009A patent/EA202191009A1/ru unknown
- 2015-04-07 IL IL295225A patent/IL295225A/en unknown
- 2015-04-07 MA MA054622A patent/MA54622A/fr unknown
- 2015-04-07 CN CN202010157115.7A patent/CN111494386A/zh active Pending
- 2015-04-07 CA CA2945151A patent/CA2945151C/en active Active
- 2015-04-07 SG SG10201912229XA patent/SG10201912229XA/en unknown
- 2015-04-07 MY MYPI2016001813A patent/MY185686A/en unknown
- 2015-04-07 MX MX2020004398A patent/MX2020004398A/es unknown
- 2015-04-07 ES ES15717381T patent/ES2829914T3/es active Active
- 2015-04-07 NZ NZ763326A patent/NZ763326A/en unknown
- 2015-04-07 MA MA39984A patent/MA39984B1/fr unknown
- 2015-04-07 KR KR1020237009340A patent/KR20230044320A/ko not_active Application Discontinuation
- 2015-04-07 MX MX2016013182A patent/MX2016013182A/es active IP Right Grant
- 2015-04-07 EP EP20191540.2A patent/EP3795152A1/en active Pending
- 2015-04-07 AU AU2015244044A patent/AU2015244044B2/en active Active
- 2015-04-07 KR KR1020167030793A patent/KR102396717B1/ko active IP Right Grant
- 2015-04-07 WO PCT/US2015/024676 patent/WO2015157257A1/en active Application Filing
- 2015-04-07 PT PT157173816T patent/PT3129021T/pt unknown
- 2015-04-07 LT LTEP15717381.6T patent/LT3129021T/lt unknown
- 2015-04-07 CA CA3158254A patent/CA3158254A1/en active Granted
- 2015-04-07 SG SG10201808870TA patent/SG10201808870TA/en unknown
- 2015-04-07 EA EA201692011A patent/EA201692011A1/ru unknown
- 2015-04-07 KR KR1020227015341A patent/KR20220066179A/ko not_active Application Discontinuation
- 2015-04-07 SG SG11201608434TA patent/SG11201608434TA/en unknown
- 2015-04-07 HU HUE15717381A patent/HUE051625T2/hu unknown
- 2015-04-07 CN CN201580018986.8A patent/CN106413716B/zh active Active
- 2015-04-07 EP EP15717381.6A patent/EP3129021B1/en active Active
- 2015-04-07 JP JP2016561810A patent/JP6537527B2/ja active Active
- 2015-04-07 NZ NZ725778A patent/NZ725778A/en unknown
- 2015-04-07 DK DK15717381.6T patent/DK3129021T3/da active
- 2015-04-07 US US14/680,659 patent/US10064866B2/en active Active
-
2016
- 2016-10-06 PH PH12016501987A patent/PH12016501987A1/en unknown
- 2016-10-06 IL IL248198A patent/IL248198B/en active IP Right Grant
- 2016-10-07 CL CL2016002566A patent/CL2016002566A1/es unknown
-
2018
- 2018-07-27 US US16/047,853 patent/US10675284B2/en active Active
-
2019
- 2019-06-04 JP JP2019104593A patent/JP6862495B2/ja active Active
-
2020
- 2020-04-05 IL IL273802A patent/IL273802B/en unknown
- 2020-05-12 US US16/872,794 patent/US20210093638A1/en not_active Abandoned
- 2020-08-05 AU AU2020213313A patent/AU2020213313B2/en active Active
- 2020-11-26 HR HRP20201887TT patent/HRP20201887T1/hr unknown
- 2020-12-07 CY CY20201101154T patent/CY1123603T1/el unknown
-
2021
- 2021-03-31 JP JP2021059028A patent/JP7206314B2/ja active Active
- 2021-11-18 IL IL288231A patent/IL288231B2/en unknown
-
2022
- 2022-07-18 AU AU2022206693A patent/AU2022206693A1/en active Pending
-
2023
- 2023-01-04 JP JP2023000189A patent/JP2023040142A/ja active Pending
- 2023-05-08 US US18/144,593 patent/US20240091234A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273802B (en) | Treatment of b-cell malignancy by a combination of jak and p13k inhibitor | |
| IL280785A (en) | Human plasma kallikrein inhibitors | |
| IL259783A (en) | Methods of treatment of malignant diseases | |
| IL248542B (en) | Procedures for making jak1 inhibitor and novel forms thereof | |
| FI3851537T3 (fi) | Hyperbilirubinemian hoito | |
| IL254093B (en) | Salts and processes for making a p13k inhibitor | |
| IL251988A0 (en) | Compounds acting on glycans and methods of using them | |
| HUE050761T2 (hu) | Vegyületek és alkalmazási eljárások | |
| IL246880A0 (en) | Tumor treatment | |
| IL256181A (en) | Means and methods for treatment of b-cell malignancies | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201403697D0 (en) | Compounds and methods of use | |
| PT3851537T (pt) | Tratamento da hiperbilirrubinemia | |
| GB201402602D0 (en) | Therapeutic uses of flavin-containing monooxygenase 3 | |
| GB201409362D0 (en) | Treatment of cancer | |
| GB201405449D0 (en) | Treatment of cancer | |
| GB201405075D0 (en) | Treatment of cancer |